The KCNN4 antibody targets the KCNN4 protein, also known as SK4 or KCa3.1. a calcium-activated potassium channel belonging to the intermediate-conductance SK family. This ion channel plays a critical role in regulating membrane potential and calcium signaling, particularly in immune cells, epithelial/endothelial cells, and certain cancer cells. KCNN4 is activated by intracellular calcium and calmodulin, facilitating potassium efflux to modulate cellular processes like volume regulation, migration, and secretion. Its expression is linked to pathologies such as sickle cell disease, inflammatory disorders (e.g., rheumatoid arthritis, colitis), and cancer progression, where it promotes tumor cell proliferation and metastasis.
KCNN4 antibodies are widely used in research to study the protein’s expression, localization, and function. Common applications include Western blotting, immunohistochemistry (IHC), flow cytometry, and immunofluorescence (IF) across experimental models. Commercial antibodies are available in polyclonal or monoclonal formats, often validated for specificity in human, mouse, or rat tissues. Researchers rely on these tools to explore KCNN4’s role in disease mechanisms or therapeutic targeting, as pharmacological blockers (e.g., TRAM-34) show potential in preclinical studies. However, antibody performance may vary depending on epitope specificity, post-translational modifications, or tissue context, necessitating rigorous validation for experimental accuracy.